American Oncology Network

Name

American Oncology Network

Legal name

American Oncology Network

Website

https://aoncology.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Community Oncology Practice Management Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621), All Other Outpatient Care Centers (621498)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Community oncology network
• Oncology practice management
• Specialty pharmacy services
• Value-based cancer care
• Clinical research oncology

Headquarters

HQ city

Fort Myers

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Practice Partnership and Management Services: AON generates revenue by partnering with independent community oncology practices, providing administrative ease, practice growth support, technology solutions, and centralized services including pathology, specialty pharmacy, and clinical trial access. Partner practices benefit from better financial outcomes while maintaining physician autonomy.
2. Specialty Pharmacy Services: AON operates an in-house specialty pharmacy that provides oral oncolytic pharmacy services to partner practices and patients, generating revenue through prescription fulfillment and pharmacy operations.
3. Value-Based Care Contracts: AON participates in CMS's Enhancing Oncology Model (EOM) and other value-based care arrangements, generating revenue through quality-focused interventions and performance-based incentives.
4. Clinical Research and Trials: AON generates revenue through clinical trial partnerships with organizations like Sarah Cannon Research Institute, Trial Library, and MiBA, providing access to cutting-edge research for partner practices.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

American Oncology Network operates as a national network of community oncology practices, providing partner practices with centralized practice management services, in-house specialty pharmacy, pathology and laboratory diagnostics, radiation and radiology services (including radioligand therapies), value-based care program participation, care coordination, behavioral health, and clinical research access. AON enables independent oncology practices to maintain physician autonomy while accessing advanced therapies (CAR T-cell, Bispecific T-cell Engager, radioligand therapies), clinical trials, and operational infrastructure typically only available at larger healthcare systems.

Product overview

American Oncology Network (AON) operates as a national network of community-based oncology practices, functioning as a platform-plus-services model. The core offering is the Practice Success Platform providing administrative ease, patient-centric care, and practice growth resources. This platform is enhanced by integrated service modules including Specialty Pharmacy, Pathology Services (with AI-enhanced karyogram segmentation via CAP-accredited Central Lab), Radiation and Radiology Services (including PET/CT and radioligand therapies), Value-Based Care programs (participating in CMS's Enhancing Oncology Model), and Care Coordination. AON has expanded into advanced immunotherapies including Bispecific T-cell Engager (BiTE) therapies at 40+ clinics and outpatient CAR T-cell therapy programs. The network also integrates behavioral health support through Colla Health partnerships and emotional peer support via CanCare. Research capabilities are powered through American Oncology Research with partnerships enabling AI-driven clinical trial matching (Trial Library), real-time data intelligence (MiBA), and traditional research collaborations (Sarah Cannon Research Institute). The network spans 21 states with over 350 providers and $2B in annual revenue.

Differentiator

Problem solved

Functional benefit

Products and services

• Practice Success Platform Comprehensive partnership platform supporting community oncology practices with patient-centric care, administrative ease, practice growth, value-based care participation (CMS Enhancing Oncology Model), and operational resources.
• Specialty Pharmacy Services
• Pathology Services
• Radiation and Radiology Services
• Value-Based Care Program
• Care Coordination
• CanCare Peer Support Program Partnership with CanCare providing free emotional peer support connecting cancer patients with trained volunteer survivors and caregivers matched by diagnosis or experience, delivered via phone, email, text, or in person.
• Colla Health Behavioral Health Services Partnership with Colla Health providing personalized behavioral health support through telehealth and phone services, including therapeutic interventions and psychiatric oversight for cancer patients.
• Clinical Research (American Oncology Research)
• Bispecific T-cell Engager (BiTE) Therapies Administration of bispecific antibody therapies in outpatient community oncology settings across 40+ clinics, with standardized protocols, staff training, and patient education materials for at-home monitoring.
• Outpatient CAR T-cell Therapy Program FDA-approved CAR T-cell therapy administration in outpatient community oncology settings, enabling advanced immunotherapy access closer to patients' homes; The Center for Cancer and Blood Disorders became one of the first community oncology practices in the U.S. to offer CAR T-cell therapy outside a hospital setting.
• Radioligand Therapies Advanced radiopharmaceutical treatments including Pluvicto (metastatic prostate cancer), Lutathera (neuroendocrine tumors), and Xofigo (bone metastases), offering targeted radiation delivery. Over 300 treatments delivered to nearly 70 patients across six partner practices.

Quantifiable outcome

• AON posted $2B annual revenue with 40% growth in 2025
• +3 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability7 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, flagship and minor.

• CanCare, Inc.coreStrategic or Co-development Partner · 11 June 2026Partnership to provide whole-person cancer care combining advanced medical treatment with emotional peer support from trained cancer survivors and caregivers. CanCare volunteers are matched with patients based on diagnosis or life experience and provide support by phone, email, text, or in person. The partnership builds on successful pilot programs at four AON partner practices and will expand nationwide.
• Colla HealthcoreStrategic or Co-development Partner · 10 June 2026Partnership to expand behavioral health services for cancer patients in community oncology settings. The collaboration addresses emotional and psychological challenges accompanying cancer diagnosis, treatment, and survivorship through telehealth and phone-based services. Launches with two AON partner practices and expands to all practices nationwide by end of 2026.
• The Ohio State University Comprehensive Cancer Center – James Cancer HospitalflagshipStrategic or Co-development Partner · 21 May 2026Zangmeister Cancer Center became an affiliate of The Ohio State University Comprehensive Cancer Center through The James Cancer Network. The affiliation increases clinical trial availability and access to advanced therapies including CAR T-cell therapy and proton therapy for central Ohio patients.
• MiBA (Meaningful Insights Biotech Analytics)coreTechnology or Integration · 15 January 2026Strategic alliance to integrate AI-enhanced data intelligence into community oncology clinical research. The alliance embeds real-time data workflows to reduce timelines between site selection and patient enrollment while improving trial accessibility and helping meet Diversity Action Plan requirements through data-driven inclusive enrollment strategies.
• Evolent HealthcoreStrategic or Co-development Partner · 6 November 2025Innovative partnership model to improve cancer care while eliminating prior authorization burden. The collaboration introduces quality-focused interventions, drives clinical insights through data and analytics platform, and rewards providers for high-quality care.
• Thyme CarecoreStrategic or Co-development Partner · 10 October 2025Collaboration developing data-driven, patient-centered, value-based oncology care. Presented nine research abstracts at ASCO Quality 2025 focusing on improving care models, policy implications, patient outcomes, and health equity based on real-world data from AON's clinical network.
• Trial LibrarycoreStrategic or Co-development Partner · 13 March 2025Partnership to expand patient access to cancer clinical trials as a care option. Trial Library uses AI-enabled platform for clinical trial matching and patient navigation. The partnership integrates clinical research into standard care delivery across AON's network of 320+ clinics and 1,500+ providers.
• Vantage Health TechnologiescoreTechnology or Integration · 29 October 2024Partnership to improve cancer patient outcomes with AI-enabled value-based care platform. Collaboration focuses on enhancing cancer care delivery through data-driven insights and value-based care optimization.
• Sarah Cannon Research InstitutecoreStrategic or Co-development Partner · 15 June 2020Cancer research collaboration expanding patient access to community-based clinical trials. AON and Sarah Cannon offer clinical trial options to patients across several locations within AON's network, with strategic research sites including Hematology Oncology Clinic and Messino Cancer Centers.
• Dignitana ABminorGTM or Marketing Partner · 28 May 2020Master contract for THOR light therapy scalp cooling technology. The Center for Cancer and Blood Disorders became the first medical oncology network in the United States to offer THOR light therapy.
• AmerisourceBergencoreStrategic or Co-development Partner · 6 March 2020Continuing strategic relationship with global healthcare solutions leader AmerisourceBergen for pharmaceutical distribution and supply chain services.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• OneOncology: Private equity-backed national network of independent community oncology practices, founded by former US Oncology executives. Direct competitor to AON in aggregating independent oncology practices and providing practice management, pharmacy, and value-based care services.
• The US Oncology Network: Subsidiary of McKesson; one of the largest community oncology networks in the US, providing practice management, technology, and clinical research support to independent oncology practices. AON's primary direct competitor and a target competitor for practice affiliation.
• Florida Cancer Specialists & Research Institute: Large independent community oncology and hematology practice in Florida with significant clinical research operations. Comparable as a high-volume community oncology provider offering advanced therapies and clinical trials outside academic centers.
• Texas Oncology: One of the largest community-based oncology practices in the US, affiliated with US Oncology Network. Operates a multi-state network of community oncology clinics with advanced therapy offerings comparable to AON's footprint.
• Tennessee Oncology / Astera Cancer Care: Large independent community oncology practice serving Tennessee and surrounding states, including OneOncology-affiliated sites. Comparable to AON in scale, advanced therapy delivery, and clinical research integration in community settings.

Broad incumbents

• Sarah Cannon Research Institute: Cancer research institute within HCA Healthcare that partners with community oncology networks (including AON) for clinical trial delivery. Adjacent rather than direct competitor, but a critical ecosystem player for community-based oncology research.
• McKesson: Parent of The US Oncology Network and a major pharmaceutical distributor (including AmerisourceBergen, an AON partner). As the incumbent aggregator in community oncology, McKesson is both a competitor (via US Oncology) and a strategic partner/distributor to AON.
• City of Hope: Major NCI-designated academic cancer center expanding community oncology affiliations (including acquisitions of community oncology groups in California). Represents the incumbent academic-system expansion that competes with AON for advanced therapy referrals and physician talent.

Emerging players

• Thyme Care: Value-based cancer care enabler partnering with AON and community oncology networks to deliver oncology navigation, care management, and risk-bearing arrangements with payers. Comparable in the value-based oncology services layer where AON is positioning.
• Pearl Health: Emerging risk-bearing primary and specialty care enablement company expanding into oncology value-based arrangements. Represents the broader shift toward risk-bearing care models that affect AON's specialty positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aoncologyllc
• YouTubeyoutube.com/channel/UChSTgwKUXjDBn_x8hV_378g
• Facebookfacebook.com/AmericanOncologyNetwork
• LinkedInlinkedin.com/company/american-oncology-network

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Oncology Network